^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Gastric Adenocarcinoma
    Drug:Enweida (envafolimab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

    Excerpt:
    ...- The tumor expresses PD-L1 as detected by the central laboratory, and the tumor proportion score (CPS) ≥ 1；...
    Trial ID:
    NCT05237349
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial.

    Published date:
    05/25/2023
    Excerpt:
    This multi-centre, single-arm, open-label study was conducted to evaluate the efficacy and safety of Envafolimab in metastatic or recurrent gastric adenocarcinoma... key inclusion criteria were previously untreated, HER2-negative, PD-L1 positive….The ORR was 50%, and DCR was 87.5%, based on RECIST v1.1....Envafolimab plus chemotherapy is a promising and tolerable therapeutic regimen for patients with metastatic or recurrent gastric adenocarcinoma.
    Secondary therapy:
    SOX
    DOI:
    10.1200/JCO.2023.41.16_suppl.e16029
    Trial ID:
    NCT05237349